Nilotinib is a medicine used to treat a type of blood cancer called chronic myeloid leukemia (CML). It works by blocking an abnormal protein that makes leukemia cells grow. It's taken by mouth as a capsule or tablet.
Every report comes from a Lived member, sent anonymously.
Have you tried Tasigna (Nilotinib) for CML (Chronic Myeloid Leukemia)?
Nilotinib is a targeted cancer medicine used to treat chronic myeloid leukemia (CML), a slowly progressing cancer of the blood-forming cells in the bone marrow. It treats Philadelphia chromosome-positive CML, the usual form of the disease, in which an exchange of genetic material between two chromosomes creates an abnormal gene called BCR-ABL. Nilotinib is approved for adults who are newly diagnosed with CML in its chronic phase, the earlier and more stable stage in which most people are diagnosed. It is also approved for adults in the chronic or accelerated phase whose leukemia did not respond well enough to imatinib (Gleevec), an older medicine of the same type, or who could not tolerate it. The original brand, Tasigna, is a capsule, and generic nilotinib capsules are also available. The capsule form (Tasigna and some generic capsules) is the only form approved for children, from 1 year of age, either newly diagnosed or after an earlier targeted drug stopped working or caused problems. Two newer brands are approved for the same adult uses: Danziten, a tablet, and Cavhanza, a tablet that dissolves on the tongue.
The BCR-ABL gene makes an abnormal enzyme, a tyrosine kinase, that is stuck in the on position. It keeps signaling white blood cells to multiply, and that unchecked signal is what drives CML. Nilotinib is a tyrosine kinase inhibitor (TKI): it binds to the BCR-ABL enzyme and holds it in its inactive shape, so the growth signal is switched off and the leukemia cells stop multiplying. In laboratory testing, nilotinib still worked against almost all of the gene changes (mutations) that make leukemia resistant to imatinib, which is why it is an option after imatinib fails. It controls the leukemia rather than reliably removing every leukemia cell, so for most people it is a long-term treatment.
Every form of nilotinib is taken twice a day, about 12 hours apart, but the forms are not interchangeable. Danziten and Cavhanza use different milligram strengths from Tasigna, so a dose of one cannot be substituted for the same number of milligrams of another. Any switch between products should go through the prescriber. Tasigna and generic capsules must be taken on an empty stomach: no food for at least 2 hours before each dose and for at least 1 hour after it. Food sharply increases how much of the drug is absorbed, which can push its effect on the heart rhythm into a dangerous range. Capsules are swallowed whole with water. For someone who cannot swallow them, the contents can be stirred into a teaspoon of applesauce and taken right away. Danziten tablets and Cavhanza orally disintegrating tablets can be taken with or without food. Danziten is swallowed whole and should not be cut, crushed or chewed. Cavhanza is handled with dry hands and placed on the tongue to dissolve; it can also be chewed or swallowed whole with water, but not crushed. If a dose is missed, skip it and take the next one at the usual time. Never take two doses together.
Common side effects include rash, itching, headache, nausea, tiredness, muscle aches and hair thinning. Constipation, diarrhea, dry skin, muscle cramps and joint pain also occur. These are usually mild to moderate and are often manageable without stopping treatment. Nilotinib can also raise cholesterol and blood sugar, which usually causes no symptoms and shows up on blood tests. Low blood counts are common, especially in the first months: fewer white cells make infections more likely, fewer platelets make bruising and bleeding easier, and fewer red cells can cause tiredness and shortness of breath. Call the care team promptly for fever, chills or other signs of infection, unexplained bruising or bleeding, or unusual weakness or shortness of breath. Bleeding that will not stop needs emergency care. Also call promptly for sudden stomach pain with nausea and vomiting, a possible sign of pancreatitis (inflammation of the pancreas); yellow skin or eyes or dark urine, which can signal liver problems; or rapid weight gain or swelling from fluid buildup. Over years of treatment, nilotinib carries a higher risk than imatinib of narrowed or blocked arteries in the heart, legs or brain. In the main trial of newly diagnosed adults, about 9% of people on the standard dose had such an event over roughly five years, compared with about 3% on imatinib. Call 911 for signs of a blocked artery or stroke (sudden chest pain, sudden leg pain, sudden numbness or weakness, trouble walking or speaking, a sudden change in eyesight, or sudden headache or confusion) or of a dangerous heart rhythm (fainting, or a racing or irregular heartbeat), which is linked to the QT effect explained under Interactions & Warnings. In children, nilotinib can slow growth, so height and development are tracked during treatment.
Nilotinib carries a boxed warning, the FDA's most prominent safety warning, because it can prolong the QT interval. This is a measurement on an electrocardiogram (ECG) of how long the heart takes to reset between beats, and a prolonged QT interval can trigger a dangerous heart rhythm. Sudden deaths have been reported. Nilotinib is not used in people with long QT syndrome or with low potassium or magnesium levels, and those levels are checked and corrected before starting and periodically afterward. An ECG is done before treatment, about a week after starting, after any dose change and periodically. The same heart rhythm risk shapes the interaction list. Other medicines that prolong the QT interval, such as many drugs used to control heart rhythm, are generally avoided. Drugs that strongly block CYP3A4, the liver enzyme that breaks down nilotinib, can roughly triple its level in the blood; ketoconazole, an antifungal, is one example. Grapefruit and grapefruit juice act on the same enzyme and should be avoided throughout treatment. Drugs that speed up that enzyme, such as rifampin (an antibiotic used for tuberculosis) and the herbal supplement St. John's wort, lower nilotinib levels and can make it less effective. With the capsules and Danziten, proton pump inhibitors for heartburn, such as esomeprazole (Nexium), reduce absorption; an H2 blocker such as famotidine (Pepcid) or an antacid, timed away from the dose, is the usual alternative. The Cavhanza label does not carry this restriction. Because nilotinib can raise cholesterol, a statin may be needed; some statins are broken down by the same enzyme, so the prescriber should review any statin, whether already taken or newly started. A pharmacist should review every prescription, over-the-counter medicine and supplement. Nilotinib can harm a developing baby. A pregnancy test is recommended before starting, along with effective contraception during treatment and for 14 days after the last dose. Breastfeeding should be avoided over the same period. A history of pancreatitis, liver disease, or heart or blood vessel disease calls for extra attention before and during treatment.
Progress on nilotinib is tracked with blood tests rather than by how a person feels; many people in the chronic phase have few symptoms once treatment is under way. The key test is a PCR (polymerase chain reaction) test, a sensitive genetic test that measures how much BCR-ABL gene activity remains in the blood, reported as a percentage on an international scale. Falling values mean the leukemia is being controlled. A major molecular response is a level of 0.1% or lower, about a thousandfold drop from a standard starting level. In the main trial in newly diagnosed adults, 44% reached it within a year on nilotinib compared with 22% on imatinib, and 77% had reached it by five years. Survival at five years was high and similar with both medicines. Blood counts are checked every 2 weeks for the first 2 months and monthly after that, along with ECGs and tests of electrolytes, lipase (a pancreas enzyme), liver function, cholesterol and blood sugar. When side effects or low blood counts become a problem, the care team often pauses treatment briefly or lowers the dose rather than stopping it for good. Some people whose leukemia stays at a very low, stable level can later try stopping under close supervision, an approach called treatment-free remission. It is considered only after at least 3 years on nilotinib with a sustained deep response on an FDA-authorized test, and only in chronic-phase disease that has never advanced. After stopping, PCR testing is frequent, monthly at first and less often over time, and continues indefinitely. In a study of people who stopped after first-line nilotinib, about half were still in remission two years later, and nearly everyone whose levels rose regained their response after restarting. Muscle, joint or bone aches can appear for a while after stopping. An unplanned stop is not the same as this monitored approach, so changes to treatment should always be made with the care team.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tasigna (Nilotinib), what you've noticed, or ask the community a question.